Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]-FF58 PET imaging in solid tumors
NCT04712721Phase 1Terminated
- Sponsor
- Novartis
- Start
- Oct 2021
- Primary completion
- Jun 2024
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 1, open-label trial of [68Ga]Ga-FF58 (4 arms), sponsored by Novartis. Primary endpoints: Time-Activity Curves from 68Ga-FF58 PET/CT images at Day 1, Standard Uptake Value mean in lesions at Day 1 and 2 more. Started Oct 2021; status: terminated.
02
Drugs
[68Ga]Ga-FF58
Beyond the preview
Go deeper on NCT04712721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04712721.